FDA Approves First IL-17A Treatment for Teens With HS

For the first time, teens with a painful, often scarring skin condition called hidradenitis suppurativa have access to a new class of biologic treatment that works differently than anything available before.

The FDA just approved secukinumab (Cosentyx) for moderate to severe HS in patients as young as 12 who weigh at least 66 pounds. It's the first IL-17A inhibitor approved for this age group, targeting a specific inflammatory protein that shows up in unusually high levels in HS-affected skin.

Hidradenitis suppurativa causes painful lumps and abscesses, usually in areas where skin rubs together like armpits and groin. More than half of all HS patients develop their first symptoms during adolescence, but diagnosis typically takes close to a decade from when symptoms first appear.

That delay matters more than it might seem. The physical toll includes scarring and disease progression, but the emotional impact during formative years affects self-image and social life when those things matter most.

Until now, teens had only one biologic option: adalimumab, a TNF-alpha inhibitor approved for this age group in 2018. Secukinumab works through a completely different mechanism, which means teenagers who haven't responded to the first treatment now have another path forward.

The approval took an unusual route because running a placebo-controlled trial in adolescent HS patients is ethically complicated. Instead, the FDA relied on pharmacokinetic modeling, using dosing data from adult HS trials combined with pediatric data from three other conditions where secukinumab is already approved, including psoriasis and juvenile arthritis.

The modeling showed that weight-based dosing in adolescents reaches drug exposure levels similar to what worked in adults. Secukinumab has been used in more than 1.8 million patients worldwide since 2015, giving families and doctors over a decade of safety data to work with.

Why This Inspires

HS diagnosed at 13 or 14 can mean decades of managing a chronic disease. Having a second biologic option with a different mechanism means more opportunity to find what actually works, especially for a condition that often goes undiagnosed for years.

For families navigating this journey, the approval represents something bigger than just another drug option. It signals that researchers and regulators are paying attention to conditions that disproportionately affect young people, even when traditional clinical trials are difficult to run.

Every teenager deserves a chance to find relief that lets them focus on being a teenager, not on managing painful symptoms that can reshape how they see themselves.